These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9868081

  • 1. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z, Zhu F, He X, Xiong S, He S.
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [Abstract] [Full Text] [Related]

  • 2. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S, Ganter MT, Furrer L, Klaghofer R, Zollinger A, Hofer CK.
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [Abstract] [Full Text] [Related]

  • 3. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ, Segal H, Yacoub M.
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [Abstract] [Full Text] [Related]

  • 4. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
    Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E.
    Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
    [Abstract] [Full Text] [Related]

  • 5. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT, Monn A, Tavakoli R, Genoni M, Klaghofer R, Furrer L, Honegger H, Hofer CK.
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [Abstract] [Full Text] [Related]

  • 6. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB.
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [Abstract] [Full Text] [Related]

  • 7. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ, Joist JH, Joiner-Maier D, Alsoufiev AL, Triantafillou AN, Goodnough LT, Santoro SA, Lappas DG.
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [Abstract] [Full Text] [Related]

  • 8. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
    Dong Y, Nuttall GA, Oliver WC, Agarwal S, Ereth MH.
    J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670
    [Abstract] [Full Text] [Related]

  • 9. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H, Szlam F, Tanaka KA, van de Locht A, Ogawa S, Levy JH.
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [Abstract] [Full Text] [Related]

  • 10. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
    Wendel HP, Heller W, Gallimore MJ, Bantel H, Müller-Beissenhirtz H, Hoffmeister HE.
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
    [Abstract] [Full Text] [Related]

  • 11. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS, Murkin JM, Adams SJ.
    Heart Surg Forum; 2004 Feb; 7(6):E599-604. PubMed ID: 15769695
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
    Tanaka KA, Szlam F, Katori N, Vega JD, Levy JH.
    Thromb Res; 2004 Feb; 113(5):333-9. PubMed ID: 15183046
    [Abstract] [Full Text] [Related]

  • 13. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA, Joen MC, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CR.
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT, Monn A, Tavakoli R, Klaghofer R, Zollinger A, Hofer CK.
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
    Feindt P, Seyfert UT, Volkmer I, Straub U, Gams E.
    Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
    [Abstract] [Full Text] [Related]

  • 19. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M, Velik-Salchner C, Stalzer B, Margreiter J, Klingler A, Streif W, Fries D, Innerhofer P.
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [Abstract] [Full Text] [Related]

  • 20. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
    Ganter MT, Dalbert S, Graves K, Klaghofer R, Zollinger A, Hofer CK.
    Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.